Treatment of cervical dystonia with botulinum toxin

Movement Disorders

Volumn 19, Issue SUPPL. 8, 2004, Pages

  Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Botulinum toxin; Cervical dystonia; Dystonia

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; TRIHEXYPHENIDYL; ANTIPARKINSON AGENT;

ARTICLE; BLADDER DISEASE; BRACHIAL PLEXUS NEUROPATHY; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONSTIPATION; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG PREFERENCE; DRY EYE; DRY NOSE; DYSPHAGIA; DYSTONIA; HUMAN; INDIVIDUALIZATION; MALAISE; MOTOR DYSFUNCTION; MUSCLE CONTRACTURE; MUSCLE WEAKNESS; NAUSEA; NECK MUSCLE; PRIORITY JOURNAL; RADICULOPATHY; SKILL; SWEAT GLAND DISEASE; VISUAL IMPAIRMENT; XEROSTOMIA; DOUBLE BLIND PROCEDURE; IMMUNOLOGY; METHODOLOGY; REVIEW; TIME; TORTICOLLIS;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; CLINICAL TRIALS; DOUBLE-BLIND METHOD; HUMANS; TIME FACTORS; TORTICOLLIS;

EID: 3042818315     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20024     Document Type: Article

References (74)

1. Tintner R, Jankovic J. Botulinum toxin for the treatment of cervical dystonia. Expert Opin Pharmacother 2001;2:1985-1994.
2. Krauss JK, Loher TJ, Pohle T, et al. Pallidal deep brain stimulation in patients with cervical dystonia and severe cervical dyskinesias with cervical myelopathy. J Neurol Neurosurg Psychiatry 2002; 72:249-256.
3. Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology 2000;55:S15-S21.
4. Ceballos-Baumann AO. Evidence-based medicine in botulinum toxin therapy for cervical dystonia. J Neurol 2001;248(Suppl. 1):14-20.
5. Comella CL, Stebbins GT, Goetz CG, et al. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord 1997;12:570-575.
6. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p 211-237.
7. Brans JWM, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996;46:1066-1072.
8. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1990;53:640-643.
9. Greene P, Kang U, Fahn S, Brin MF, Moskowitz C, Flaster E. Double-blind, placebo controlled trial of botulinum toxin injection for the treatment of spasmodic torticollis. Neurology 1990;40: 1213-1218.
10. Lorentz IT, Subramanian SS, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord 1991;6:145-150.
11. Poewe W, Schlosky L, Kleedorfer B, et al. Treatment of spasmodic torticollis with local injections of botulinum toxin. J Neurol 1992; 239:21-25.
12. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;41:277-280.
13. Jankovic J. Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol 1991;48:1253-1256.
14. Jankovic J, Brin MF, Comella C. Handbook of botulinum toxin treatment for cervical dystonia. New York: Churchill Livingstone; 1994.
15. Koller W, Vetere-Overfield B, Gray C, Dubinsky R. Failure of fixed-dose, fixed muscle injection of botulinum toxin in torticollis. Clin Neuropharmacol 1990;13:355-358.
16. Jahanhashi M, Marsden CD. Psychological functioning before and after treatment of torticollis with botulinum toxin. J Neurol Neurosurg Psychiatry 1992;55:229-231.
17. Garner CG, Straube A, Witt TN, et al. Time course effects of local injections of botulinum toxin. Mov Disord 1993;8:33-37.
18. Vieregge P, Kompf D. Brachial plexopathy after botulinum toxin administration for cervical dystonia. J Neurol Neurosurg Psychiatry 1993;56:1338-1339.
19. Comella CI, Tanner CM, DeFoor-Hill L, Smith C. Dysphagia after botulinum toxin injections for spasmodic torticollis. Clinical and radiologic findings. Neurology 1992;42:1307-1310.
20. Buchman AS, Comella CL, Stebbins GT, et al. Determining a dose-effect curve for botulinum toxin in the sternocleidomastoid muscle in cervical dystonia. Clin Neuropharmacol 1994;17:188-193.
21. Jankovic J, Schwartz K. Longitudinal follow-up of botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993;43:834-836.
22. Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000;15:150-153.
23. Hsiung G-YR, Das SK, Ranawaya R, Lafontaine A-L, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17:1288-1293.
24. Sloop RR, Patel MC. Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals. Mov Disord 2001;16:100-105.
25. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport7. J Neurol Neurosurg Psychiatry 1998;64:13-17.
26. Odergren T, Hjalatason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport7 and BOTOX in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12.
27. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double-blind, randomized, cross-over study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-462.
28. Moyer E, Settler PE. Botulinum toxin type B: experimental and clinical experience. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p 71-86.
29. Tsui JKC, Hayward M, Mak EKM, Schulzer M. Botulinum toxin type B in the treatment of cervical dystonia: a pilot study. Neurology 1995;45:2109-2110.
30. Lew MF, Adomato BT, Duane DD, et al. Botulinum toxin type B (BotB): a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-707.
31. Figgitt DP, Noble S. Botulinum toxin B. A review of its therapeutic potential in the management of cervical dystonia. Drugs 2002; 62:705-755.
32. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-1446.
33. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-1438.
34. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 2003;250:967-969.
35. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49:34-38.
36. Chen R, Karp BI, Hallett M. Botulinum toxin type F for treatment of dystonia: long-term experience. Neurology 1998;51:1494-1496.
37. Greene PE, Fahn S. Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord 1996;11:181-184.
38. Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry 1998;64:577-580.
39. Goldman S, Ahlskog JE. Posttraumatic cervical dystonia. Mayo Clin Proc 1993;68:443-448.
40. Brashear A, Ambrosius WT, Eckert GJ, Siemers ER. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998;13:158-161.
41. Wissel J, Masuhr F, Schelosky L, et al. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord 1997;12:722-726.
42. Dressler D. Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. Eur J Neurol 2000;7:713-718.
43. Sheean GL. The management of spasticity with botulinum toxin. Euro J Neurol 1997;4(Suppl. 2):S41-S45.
44. Brans JWM, Aramideh M, Koelman JHTM, et al. Electromyography in cervical dystonia. Changes after botulinum and trihexyphenidyl. Neurology 1998;51:815-819.
45. Jankovic J. Needle EMG guidance is rarely required. Muscle Nerve 2001;24:1568-1570.
46. Speelman JD, Brans JW. Cervical dystonia and botulinum treatment: is electromyographic guidance necessary? Mov Disord 1995;10:802.
47. Comella CL, Buchman AS, Tanner CM, et al. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992;42:878-882.
48. Gelb DJ, Yoshimura DM, Olney RK, et al. Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol 1991;29:370-376.
49. Erdal J, Ostergaard L, Fuglsang-Frederiksen A, Werdelin L, Dalager T, Sjo O, et al. Long-term botulinum toxin treatment of cervical dystonia--EMG changes in injected and noninjected muscles. Clin Neurophysiol 1999;110:1650-1654.
50. Greene P, Kang U, Fahn S, Brin MF, Moskowitz C, Flaster E. Double-blind, placebo controlled trial of botulinum toxin injection for the treatment of spasmodic torticollis. Neurology 1990;40: 1213-1218.
51. Moore AP, Blumhardt LS. A double blind trial of botulinum toxin "A" in torticollis with one year follow up. J Neurol Neurosurg Psychiatry 1991;54:813-816.
52. Jankovic J. Botulinum toxin: clinical implications of antigenicity and immunoresistance. In: Brin MF, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams and Wilkins; 2002. p 409-416.
53. Göschel H, Wolhfart K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies - therapeutic consequences. Exp Neurol 1997;147:96-102.
54. Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998;50:1624-1629.
55. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 1999;66:612-616.
56. Atassi MZ, Oshima M. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol 1999;19:219-260.
57. Hatheway CL, Dang C. Immunogenicity of the neurotoxins of clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p 93-108.
58. Dressler D, Dirnberger G, Bhatia K, et al. Botulinum toxin antibody testing: comparison between the mouse diaphragm assay and the mouse lethality assay. Mov Disord 2000;15:973-976.
59. Dressler D, Bigalke H, Rothwell JC. The stemocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans. J Neurol 2000;247:630-632.
60. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 1998;13:150-154.
61. Dressler D, Bigalke H. Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy. Mov Disord 2002;17:170-173.
62. Siegel LS. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralizing test and by an enzyme-linked immunoabsorbent assay. J Clin Microbiol 1988;26: 2351-2356.
63. Dressler D, Dirnberger G, Bhatia KP, et al. Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. Mov Disord 2000;15:973-976.
64. Palace J, Nairne A, Hyman N, et al. A radioimmunoprecipitation assay for antibodies to botulinum A. Neurology 1998;50:1463-1466.
65. Dressler D, Dirnberger G. Botulinum toxin antibody testing: comparison between an immunoprecipitation assay and the mouse diaphragm assay. Eur Neurol 2001;45:257-260.
66. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8(Suppl. 5):21-29.
67. Benabou R, Brin MF, Doucette JT. Cervical dystonia: a retrospective study on safety and efficacy of BOTOX lots 79-11 and 2024. Neurology 1999;52(Suppl. 2):A117-A118.
68. Racette BA, McGee-Minnich L, Perlmutter JS. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation. Clin Neuropharmacol 1999;22:337-339.
69. Jankovic J, Davis T, Wooten-Watts M, and the BOTOX Cervical Dystonia Retrospective Study Group. The Safety of BOTOX (Botulinum Toxin Type A) Prepared from new US bulk toxin is comparable to the original in cervical dystonia treatment: a retrospective analysis. Mov Disord 2000;15(Suppl. 2):31.
70. BOTOX (Botulinum Toxin Type A), Purified Neurotoxin Complex, Product Information. Online at http://www.botox.com/prescribing_info.html, 2000.
71. MYOBLOC. Online at http://www.myobloc.com/product_information/full_prescribing_info.pdf.
72. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003;60:1186-1188.
73. Eleopra R, Tugnoli V, Rossetto O, et al. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 1997;224:91-94.
74. Truong DD, Cullis PA, O'Brien CF, et al. BotB (Botulinum toxin type B): evaluations of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (Preliminary study). Mov Disord 1997;12:772-775.